According to Fortune Business Insights, the global pharmacy benefit management market was worth roughly $609.13 billion in 2025 and is on track to reach about $646.61 billion in 2026. The firm projects the market will climb to nearly $991.88 billion by 2034, implying a compound annual growth rate of 5.5% across the 2026–2034 forecast window. This steady expansion reflects the growing role PBMs play as intermediaries between insurers, pharmacies, and drug manufacturers, negotiating pricing and managing prescription drug spending on behalf of health plans.
What's Driving Growth
Several structural forces underpin this trajectory. Chronic disease prevalence continues to climb worldwide, pushing up demand for both everyday maintenance medications and costly specialty drugs used to treat cardiovascular, respiratory, and metabolic conditions. At the same time, drug price inflation has been a persistent pressure point—branded drug prices rose meaningfully in recent years, and this has made cost-containment services more valuable to insurers and employers footing the bill. Prescription volumes have grown alongside this: billions of prescriptions are now filled annually in the U.S. alone, creating enormous administrative and financial complexity that PBMs are positioned to manage.
Technology adoption is also reshaping how PBMs operate. Machine learning and AI tools are increasingly used to automate claims processing, flag fraudulent claims, and optimize drug pricing decisions in real time. Some major players have rolled out pricing-comparison tools that let members find the lowest available cost for a medication, whether that price comes through their insurance benefit or an independent discount channel. These digital capabilities are becoming a competitive differentiator as PBMs try to demonstrate value amid growing scrutiny of their pricing practices.
Get a Free Sample PDF - https://www.fortunebusinessinsights.com/enquiry/request-sample-pdf/pharmacy-benefit-management-pbm-market-103496
Headwinds
Not everything favors continued expansion. A persistent criticism of the PBM industry is the lack of transparency around how revenue is earned and distributed across the drug supply chain. Research cited in the report suggests that more than half of total spending on brand-name medicines flows to supply-chain intermediaries—including PBMs—rather than directly to drug manufacturers. This opacity has made some insurers and manufacturers wary of PBM partnerships, and it remains a key restraint on broader market adoption, particularly as lawmakers apply more scrutiny to pricing practices industry-wide.
Market Segments
By service line, specialty pharmacy services represented the largest share of the market in 2026, driven by growing demand for more affordable access to high-cost treatments for chronic and rare diseases. Meanwhile, benefit plan design and administration is expected to be the fastest-growing service segment, aided by rising enrollment in programs like Medicare Advantage, which covered roughly 31 million Americans as of 2023.
By service provider type, insurance companies currently lead the market, a position reinforced by ongoing consolidation and partnerships between insurers and PBM operators. Retail pharmacies, however, are expected to grow fastest going forward, aided by major retail entrants such as Amazon and Walmart building out pharmacy operations.
Competitive Landscape
The market remains concentrated among a handful of major players. CVS Health, OptumRx, and Cigna's Express Scripts unit are identified as the dominant companies, with additional significant activity from Anthem (through its CarelonRx unit), Centene, Abarca Health, and MedImpact. Recent years have seen active dealmaking and product launches across the sector—including CVS's 2023 rollout plans for a new pricing model, OptumRx's 2023 changes to its insulin formulary, and Centene's 2022 acquisition of Magellan Health—as companies compete on both pricing transparency and service breadth.
Outlook
Taken together, Fortune Business Insights' data points to a PBM market that will keep growing steadily through 2032, propelled by rising chronic disease burden, higher drug prices, and expanding insurance coverage. At the same time, the industry faces real pressure to address transparency concerns, which could shape how quickly adoption grows in segments where insurers and manufacturers have grown more cautious about PBM partnerships.